Search
for
Sort by
Research 30 of 1000+
- Natural variability and the influence of concurrent control values on the detection and interpretation of low-dose or weak endocrine toxicities.
- Problems Associated with the Recognition and Confirmation of Low-Dose Endocrine Toxicities
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Endocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients
- 44391 ICI Therapy Toxicities in Psoriasis
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
- The Many Faces of Calcineurin Inhibitor Toxicity—What the FK?
- Management of the adverse effects of targeted therapy for cancer
- Alopecia With Endocrine Therapies in Patients With Cancer
- Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer
- Non polycystic ovary syndrome–related endocrine disorders associated with hirsutism
- Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Dermatological adverse events with taxane chemotherapy
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Systemic causes of hair loss
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
- Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
- Early lead exposure and pubertal development in a Mexico City population
- Oral minoxidil for late alopecia in cancer survivors
- Cancer-Related Alopecia: From Etiologies to Global Management
- Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part III on Psychosexual Therapy and the Masculine Self-Esteem)
- The Effects of Environmental Pollutants and Exposures on Hair Follicle Pathophysiology
- Cytostatics and immunosuppressive drugs